All stocks ยท VANTABIO
VB

Vanta Bioscience Limited

VANTABIO BSE Diagnostics & Research Healthcare

Vanta Bioscience Limited, together with its subsidiaries, operates as a preclinical contract research organization in India. The company offers a range of services in method development, validation, impurity profiling, โ€ฆ

ISIN INE695X01011
Listed โ€”
Quarters tracked โ€”
Filings 14 docs

About

Vanta Bioscience Limited, together with its subsidiaries, operates as a preclinical contract research organization in India. The company offers a range of services in method development, validation, impurity profiling, impurity isolation, characterization, certification and evaluation, mammalian and genetic toxicology, drug metabolism, pharmacokinetics, and bio-analysis during the preclinical stage of drug development. It also provides testing services for agrochemicals and chemicals, such as physico-chemical testing; sub-acute, sub-chronic, and chronic; toxicokinetics assessment, CoA and dose formulation analysis, 5 batch analysis, and studies on behavior in water, soil and air, bioaccumulation, as well as acute 6 pack, carcinogenicity, genetic toxicity, DART, eco-toxicity, and alternative to animal studies. In addition, it offers diet formulation services, which include starter material processing, proximate and composition analysis, diet balancing and formulation, irradiation, and packaging and labeling; and batch release pharmacopoeia tests, such as pyrogen testing, stability studies, and abnormal toxicity and impurity profiling. Further, the company provides services to medical device industry including cytotoxicity, intracutaneous/mucous membrane irritation, dermal sensitization, mutagenicity assays, acute systemic toxicity, and implantation tests. Additionally, it is involved in the provision of risk assessment services to evaluate the active pharmaceutical ingredients, excipients, extractable, leachables, and pharmaceutical impurities; and expert services to determine health-based exposure limits for permitted daily exposure or allowable daily exposure, including occupational exposure limits. The company offers its services to pharmaceutical, medical devices, nutraceuticals, feed additive, biotech, agrochemicals, cosmetics, and chemical industries. Vanta Bioscience Limited was incorporated in 2016 and is based in Secunderabad, India.

Quarterly Results

No quarterly results synced yet for this stock.

Data is backfilled from screener.in โ€” check back soon.

Profit & Loss

Annual ยท Rs. Crores
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Sales 1.821.138.565.179.069.8213.7212.083.880.00
Expenses 0.792.794.915.655.665.929.408.812.840.00
Operating Profit 1.03-1.663.65-0.483.403.904.323.271.040.00
OPM % 56.59-146.9042.64-9.2837.5339.7131.4927.0726.80โ€”
Other Income 0.160.040.050.630.170.020.110.230.050.00
Interest 0.780.662.423.112.112.061.951.690.200.00
Depreciation 0.390.441.241.251.321.251.190.710.570.00
Profit before tax 0.02-2.720.04-4.210.140.611.291.100.320.00
Tax % -450.00-2.21-25.000.7142.8621.3124.0336.3690.62โ€”
Net Profit 0.12-2.660.05-4.240.080.470.980.690.030.00
EPS in Rs 0.17-4.210.08-6.720.130.741.551.090.050.00
Dividend Payout % 0.000.000.000.000.000.000.000.000.00โ€”

Balance Sheet

Annual ยท Rs. Crores โ€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Equity Capital 7.116.316.316.316.316.316.316.315.733.65
Reserves 14.1410.8213.4813.4317.6817.6017.1315.9310.862.50
Borrowings 38.0830.4725.3825.7620.7717.2814.1513.2511.187.50
Other Liabilities 6.788.237.746.145.645.064.002.511.400.10
Total Liabilities 66.1155.8352.9151.6450.4046.2541.5938.0029.1713.75
Fixed Assets 48.0842.4337.8737.4036.1229.3920.7617.9017.4912.95
CWIP 0.000.000.000.000.000.000.003.702.340.00
Investments 3.003.003.003.003.003.003.003.954.500.00
Other Assets 15.0310.4012.0411.2411.2813.8617.8312.454.840.80
Total Assets 66.1155.8352.9151.6450.4046.2541.5938.0029.1713.75

Cash Flows

Annual ยท Rs. Crores โ€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Cash from Operating Activity 0.001.364.550.646.7011.013.17-0.06-6.75-0.26
Cash from Investing Activity 0.00-5.79-1.67-2.53-8.08-9.96-1.56-4.70-7.53-12.95
Cash from Financing Activity 0.004.43-2.811.881.38-1.07-1.804.9613.9313.66
Net Cash Flow 0.000.000.070.000.00-0.02-0.200.20-0.360.44
Free Cash Flow 0.00-4.432.88-1.89-1.351.152.82-2.54-14.21-13.21
CFO/OP % 0.00-82.00125.00-133.00197.00282.0073.00-2.00-649.00โ€”

Ratios

Annual ยท Days / % โ€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018
Debtor Days 513.41562.0499.78135.5529.0173.5936.1847.1431.04
Inventory Days โ€”2,389.09โ€”โ€”โ€”โ€”โ€”2,409.003,444.69
Days Payable โ€”991.77โ€”โ€”โ€”โ€”โ€”119.93228.12
Cash Conversion Cycle 513.411,959.3699.78135.5529.0173.5936.182,336.213,247.61
Working Capital Days 629.73-2,687.43-98.5057.1938.2796.27272.95260.76190.03
ROCE % 1.50-4.445.34-2.445.246.738.818.092.27

Shareholding Pattern

% holding โ€” latest first
Holder Mar 2026 Sep 2025 May 2025 Mar 2025 Sep 2024 Mar 2024 Sep 2023 Mar 2023 Sep 2022 Mar 2022 Sep 2021 Mar 2021
Promoters 72.81 72.81 72.81 69.36 69.36 69.36 69.36 69.36 69.36 69.00 69.00 69.11
Public 27.18 27.19 27.18 30.64 30.64 30.64 30.64 30.65 30.64 31.00 31.00 30.89
No. of Shareholders 426 419 408 408 424 418 388 394 393 409 412 361

Corporate Actions

No corporate actions recorded.

Announcements

5 filings